| Prev Close | 9.56 |
| Open | 9.53 |
| Day Low/High | 9.40 / 9.66 |
| 52 Wk Low/High | 4.20 / 10.54 |
| Volume | 237.74K |
| Avg Volume | 433.60K |
| Exchange | NASDAQ |
| Shares Outstanding | 54.67M |
| Market Cap | 513.87M |
| EPS | -1.10 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that President and Chief Executive Officer, Hany Massarany, will attend the 2017...
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has achieved CE Mark under the European In-Vitro Diagnostic Devices Directive...
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the upsizing and pricing of its previously announced underwritten public offering of...
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that it has commenced an underwritten public offering of $65,000,000 of shares of...
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has received 510(k) market clearance from the U.
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 2017 William Blair Growth Stock Conference in Chicago on Tuesday, June 13, 2017.
Investors in GenMark Diagnostics, Inc. saw new options begin trading this week, for the May 19th expiration.
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas, Nevada,...
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the first quarter ended March 31, 2017.
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has achieved CE Mark under the European In-Vitro Diagnostic Devices...
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 2, 2017.
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 16 th Annual Needham Healthcare Conference to be held at the Westin Grand...
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at Cowen and Company's 37 th Annual Health Care Conference to be held at the Marriott...
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2016.
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its fourth quarter earnings results after market close on Tuesday, February 28, 2017.
Here's a technical look at how to trade stocks rising with unusual volume flow.
In trading on Tuesday, shares of GenMark Diagnostics, Inc. touched a new 52-week high of $13.42/share.
Traders, pressed to find some action, are chasing certain things to a ridiculous extent.
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported preliminary fourth quarter 2016 revenue of $14.
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 2017 J.
Investors eyeing a purchase of GenMark Diagnostics, Inc. shares, but tentative about paying the going market price of $12.23/share, might benefit from considering selling puts among the alternative strategies at their disposal.
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has submitted 510(k) applications to the FDA for its ePlex sample-to-answer...
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the third quarter ended September 30, 2016.
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the...
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Thursday, November 3, 2016.
Cowen lifted GenMark Diagnostics (GNMK) stock rating to 'outperform,' citing positive reception of its ePlex device.
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the second quarter ended June 30, 2016.
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the 36th...
